ReproCELL
Leading global supplier of iPS-derived cells, stem cell reagents, human biofluids, and 3D cell culture.
About This Fund
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK) and BioServe (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
Investment Focus
What They Look For
bio-venture companies expected to reach business phase in 5-7 years; Japan, US, EU; evaluated on industry knowledge, business potential, technology by ReproCELL
Preparing to pitch ReproCELL?
CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.
Analyze My Deck →